Posts
Protein A colorimetric resins are the most extensively used
affinity purifiers in bio-manufacturing and other industries. Protein A
colorimetry is a robust, high-throughput chromatography method and is used
primarily as a capture step because of its inherent precision.
Market Dynamics
Approval and launch of new biosimilars is expected to propel
growth of the protein A resin market. For instance, in December 2020, Sandoz
Canada Inc., a generics and biosimilars manufacturer and a division of the
Switzerland-based multinational Novartis AG, received Health Canada authorization
for Hyrimoz (adalimumab injection, reference biologic drug: Humira) on November
4, 2020 for marketing in Canada. Hyrimoz, the new biosimilar, has been approved
for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic
arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease,
ulcerative colitis, hidradenitis suppurativa, psoriasis and adult uveitis.
Moreover, high prevalence of chronic diseases is also expected to
aid in growth of the protein A resin market. For instance, according to the
American Cancer Society, in 2019, there will be an estimated 1,762,450 new
cancer cases diagnosed and 606,880 cancer deaths in the U.S.
Increasing adoption of chromatography resins is expected to propel
growth of the protein A resin market. For
instance, in March 2020, Purolite Ltd. announced to supply its Praesto Jetted
A50, an agarose-based Protein A chromatography resin, for use as part of the
commercial manufacturing process of an FDA-approved monoclonal antibody
treatment by a contract manufacturing organization. Similarly, in November
2020, Purolite Ltd. announced to supply its Protein A capture resin, Praesto
Jetted A50 to WuXi Biologics, a global company with leading open-access
biologics technology, for immediate use. WuXi Biologics.
Emergence of Covid-19 is expected to offer lucrative growth
opportunities for players in the protein A resin market. For instance, in
October 2020, Repligen Corporation and Navigo Proteins GmbH, a premier protein
engineering company, announced their successful development of an affinity
ligand targeting the spike protein, to be utilized in the purification of
COVID-19 vaccines.
Competitive Analysis
Major players operating in the global protein A resin market
include, GE Healthcare, Thermo Fisher Scientific, Repligen, Avantor, Inc., Purolite
Ltd., Tosoh Bioscience, EMD Millipore, Novasep, GenScript Biotech Corporation,
Purolite Life Sciences, and Expedeon Ltd.
Major players operating in the global protein A resin market are
focused on approval and launch of new products to expand their product
portfolio. For instance, in March 2020, Avantor, Inc. launched a new
recombinant Protein A affinity chromatography resin used to purify antibodies
during mAbs production.
No comments:
Post a Comment